ECO
Onco
Daily
Twitter
Facebook
Youtube
RSS Feed
Linkedin
Facebook
RSS
Twitter
Youtube
Linkedin
July, 2024
July 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
« Jun
ECO
Apr 17, 2024, 19:08 |
Blog
The Joint Euro-American Forum on Cancer takes place in Dublin on 25-26 April - European Cancer Organisation
European Cancer Organisation shared on LinkedIn: "The Joint Euro-American Forum on Cancer takes place in Dublin…
Mar 27, 2024, 21:15 |
Blog
Dégi László Csaba: Joining the ENOHE International Relations Committee is truly a great honor
Dégi László Csaba, President of European Cancer Organization, posted on LinkedIn: "Joining the ENOHE International…
Feb 8, 2024, 21:54 |
Blog
We met Conf. Carmen Orban to discuss how ECO can support in implementing HPV elimination policies - European Cancer Organisation
European Cancer Organisation made the following post on LinkedIn: "We met Conf. Carmen Orban, the Romanian…
Jan 25, 2024, 17:51 |
Blog
It’s time to accelerate the use of patient-reported outcome measures in European oncology - European Cancer Organisation
European Cancer Organisation shared a post on LinkedIn: “It’s time to accelerate the use of patient-reported…
Oct 1, 2023, 12:45 |
Positive
100 Influential Women in Oncology: Key Opinion Leaders to follow on Social Media in 2023: Part 6
In August, OncoDaily began its series on '100 Influential Women in Oncology: Key Opinion Leaders…
Aug 26, 2023, 02:44 |
Societies
Will you be attending ESMO in Madrid? If so, please fill out the attendance interest survey for a 1-day ASCO-ECO workshop
The Fundación para la Excelencia y la Calidad de la Oncologia (ECO) partners with ASCO…
1
2
3
All:
26
Posts:
21 - 30
We need to hurry up, because cancer and patients cannot wait!
Eliot Levitt: The Yvonne Awards demonstrate something that it doesn't hurt to be reminded of
New data from the NEST clinical trial was presented at ESMOGI24 - Agenus
Zainab Shinkafi-Bagudu's latest commentary on Cervical Cancer Elimination Forum
New Paper Alert! Amivantamab-Lazertinib Improves Outcomes in High-Risk EGFR-Mutant NSCLC Subgroups: MARIPOSA Study Results
Facebook
RSS Feed
Twitter
Linkedin
Youtube